Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology (PDSB) announced a virtual Key Opinion Leader event scheduled for June 17, 2025, focusing on HPV16-positive head and neck squamous cell carcinoma (HNSCC). The event will feature experts Dr. Kevin Harrington and Dr. Katharine Price discussing the unmet needs and treatment landscape for recurrent/metastatic HPV16+ HNSCC. The webinar will examine HNSCC in relation to Merck's KEYNOTE-689 study and address the increasing cases of HPV16+ HNSCC in the US and Europe. A key focus will be Versamune® HPV, PDS Biotech's investigational immunotherapy currently in Phase 3 trials in combination with pembrolizumab for first-line treatment of R/M HPV16+ HNSCC, as well as in Phase 2 trials for various HPV16-positive cancers. The event will explore the differences between HPV-positive and HPV-negative HNSCC as distinct diseases.

PDS Biotech (PDSB) presented updated data from the VERSATILE-002 trial evaluating Versamune HPV (PDS0101) for head and neck cancers at ASCO 2025. The trial showed durable median overall survival of 30.0 months in first-line recurrent/metastatic HPV16-positive HNSCC patients, with a 95% CI lower limit of 23.9 months. The study demonstrated an objective response rate of 35.8% and disease control rate of 77.4% across all patients (CPS ≥ 1). Notably, patients with CPS ≥ 20 showed improved outcomes with 39.3 months median overall survival and 47.6% objective response rate. The results are particularly significant as HPV16-positive HNSCC represents over 50% of HNSCC cases in the US and has shown worse survival outcomes compared to other HNSCC types. VERSATILE-003, the company's ongoing Phase 3 trial, is the only registrational study specifically targeting HPV16-positive HNSCC patients.

PDS Biotech (NASDAQ: PDSB) announced significant extended follow-up data from its VERSATILE-002 trial and additional studies of Versamune® HPV to be presented at ASCO 2025. The VERSATILE-002 trial showed remarkable survival rates in HPV16-positive head and neck cancer patients: 39.3 months median overall survival for CPS ≥20 patients (vs ~15 months with pembrolizumab alone) and 30.0 months for CPS ≥1 patients (vs ~12 months with pembrolizumab). The ongoing Phase 3 VERSATILE-003 trial will enroll 351 patients to evaluate Versamune® HPV with pembrolizumab as first-line treatment. Additionally, a Phase 2 trial showed promising results with 70% stable disease rate using Versamune® HPV alone and 100% stable disease or partial response when combined with pembrolizumab in newly diagnosed patients.

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, announced its participation in the A.G.P. Virtual Annual Healthcare Company Showcase on May 21, 2025. CEO Frank Bedu-Addo will engage in a fireside chat from 5:20 to 5:40 p.m. ET. The virtual event will provide opportunities for one-on-one investor meetings with the PDS Biotech leadership team. A replay and transcript of the fireside chat will be available on the company's website after the event.

PDS Biotech (PDSB) reported its Q1 2025 financial results and provided clinical updates. The company has initiated the VERSATILE-003 Phase 3 trial for Versamune® HPV in HPV16-positive head and neck cancer, with Mayo Clinic sites recently added. The trial will include approximately 350 patients and received FDA Fast Track designation. Financial highlights include a net loss of $8.5 million ($0.21 per share), improved from $10.6 million in Q1 2024. R&D expenses decreased to $5.8 million from $6.7 million, while G&A expenses were $3.3 million. The company's cash balance stood at $40 million as of March 31, 2025. PDS Biotech also completed a registered direct offering raising approximately $11 million, with potential for additional $11 million from warrant exercises.

PDS Biotechnology (PDSB), a late-stage immunotherapy company focused on cancer treatment, has granted a nonstatutory stock option to a new clinical department employee. The inducement grant, issued on May 5, 2025, allows the purchase of 5,000 shares of common stock at an exercise price of $1.31 per share. The stock option follows a four-year vesting schedule, with 25% vesting after the first year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.

PDS Biotechnology (NASDAQ: PDSB) presented preclinical data on their Infectimune®-based universal flu vaccine at IMMUNOLOGY2025™. Two key presentations highlighted promising results: Dr. Andrea Sant demonstrated that Infectimune® generated a significantly higher frequency of multifunctional influenza-specific CD4 T cells with cytotoxic properties, particularly targeting lung tissue in subjects with prior flu exposure. Dr. James Allen's research showed that Infectimune®-based vaccines using COBRA antigens effectively neutralized and protected against multiple H3N2 influenza strains from 2014-2021 in ferret studies. The research was funded and conducted by NIAID's CIVR-HRP, allowing PDS Biotech to maintain focus on their core immuno-oncology programs, including the VERSATILE-003 Phase 3 trial for HPV-positive head and neck cancer.

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its Q1 2025 financial results conference call and webcast for May 14, 2025, at 8:00 AM ET. The company will present its financial performance for the quarter ending March 31, 2025, along with updates on its clinical programs. Investors can join via phone (1-877-704-4453 domestic, 1-201-389-0920 international) or through the webcast. The presentation will be archived on PDS Biotech's website for six months following the live event.

PDS Biotechnology (NASDAQ: PDSB) has announced the acceptance of three abstracts featuring Versamune® HPV (PDS0101) for presentation at the 2025 ASCO Annual Meeting in Chicago from May 30-June 3, 2025.

The presentations include:

• VERSATILE-003: A Phase 3 randomized trial comparing PDS0101 and Pembrolizumab vs. Pembrolizumab alone for first-line treatment of HPV16-positive recurrent/metastatic head and neck cancer
• VERSATILE-002: Results on overall survival in HPV16 positive recurrent/metastatic head and neck cancer patients treated with PDS0101 and Pembrolizumab
• MC200710: Initial results of PDS0101 alone or with pembrolizumab in locally advanced HPV-associated oropharyngeal carcinoma